PREMAQUICK: Evaluation of a New Predictive Test of Preterm Birth in Case of Threatened Preterm Labor

Sponsor
University Hospital, Strasbourg, France (Other)
Overall Status
Recruiting
CT.gov ID
NCT04374916
Collaborator
(none)
200
1
1
24.4
8.2

Study Details

Study Description

Brief Summary

Threatened preterm labor (TPL) is defined by cervical changes and regular and painful uterine contractions occurring between 24 and 36 + 6 weeks of gestation that may or may not lead to premature labor and delivery. There is no reliable way to predict preterm delivery.

The study's hypothesis is that the Premaquick® test can improve the prediction of preterm delivery.

The investigators also want to compare this test with the Partosure® (Placental alpha microglobulin-1) test.

Condition or Disease Intervention/Treatment Phase
  • Device: Premaquick®
  • Device: PARTOSURE®
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Evaluation of a New Predictive Test of Preterm Birth in Case of Threatened Preterm Labor
Actual Study Start Date :
Aug 11, 2020
Anticipated Primary Completion Date :
Aug 25, 2022
Anticipated Study Completion Date :
Aug 25, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Partosure® test + Premaquick® test

All patients will have the same 2 tests.

Device: Premaquick®
Vaginal secretions are collected prior to any vaginal or endovaginal ultrasound examination to avoid false positives, with the nylon swab provided with the test (placed in the posterior fornix of the vagina for 10 seconds).Then the samples are tested with the Premaquick test. Results are obtained in 10 minutes.

Device: PARTOSURE®
An immunochromatographic test wich determines the qualitative in vitro detection of placental alpha microglobulin-1 (PAMG-1) in cervico-vaginal secretions.

Outcome Measures

Primary Outcome Measures

  1. The primary outcome measure will be the occurrence of a premature delivery within 7 days after patient's inclusion. [The outcome measure is assessed at visit 2 (day 7), 7 days after the inclusion visit.]

Secondary Outcome Measures

  1. Collection of the occurrence of a premature delivery within 7 days of inclusion, then calculation of specificity, positive and negative predictive values. [At visit 2, Day 7 (7 days after inclusion visit V0)]

  2. Collection of the occurrence of a premature delivery on Day 2 and Day 14 following the inclusion, then calculation of the sensitivities, specificities, positive and negative predictive values. [At visit 1, Day 2 (2 days after inclusion visit ) and D14 (14 days after inclusion visit )]

  3. Collection of the number of invalid results requiring restarting the Premaquick test. [At the Inclusion visit Visit 0 (Day 0)]

  4. Collection of premature deliveries at different times (2, 7 and 14 days after inclusion visit), then comparison of the sensitivities and specificities of the two tests at different times. [At visit 1 (Day 2) - Visit 2 (Day 7) and after end of research visit (Day 14)]

  5. a new calculation algorithm to predict the risk of preterm delivery, based on the results observed in this study. [At visit 1 (Day 2) - Visit 2 (Day 7) and after end of research visit (Day 14)]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient aged > 18 years (with no upper age limit)

  • Patient affiliated to a social security health regime

  • Between 24 and 33 + 6 weeks of gestation (amenorrhea)

  • Singleton pregnancy

  • Patient with a TPL: Uterine contractions during the last 24 hours felt by the patient, painful or not, and cervix less than or equal to 25 mm on endovaginal ultrasound

  • Having signed an informed consent form

Exclusion Criteria:
  • Twin pregnancy

  • Sexual intercourse less than 24 hours from inclusion

  • Cervical cerclage

  • Abundant metrorrhagia

  • Premature rupture of membranes

  • Pre-eclampsia

  • Congenital malformation

  • Presence of a placenta previa

  • Pelvic examination in the previous 24 hours (compared to inclusion)

  • Patient under guardianship, curatorship or safeguard of justice

  • Persons deprived of their liberty by judicial or administrative decision

  • Persons under psychiatric care under duress

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hôpitaux Universitaires de Strasbourg Strasbourg France 67091

Sponsors and Collaborators

  • University Hospital, Strasbourg, France

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier:
NCT04374916
Other Study ID Numbers:
  • 7353
First Posted:
May 5, 2020
Last Update Posted:
Oct 7, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Strasbourg, France
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 7, 2021